---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000683"
form_type: "8-K"
ticker: "TECH"
cik: "0000842023"
company_name: "BIO-TECHNE Corp"
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T12:19:43.215405+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bio-Techne Q2 organic revenue down 2% to $272.6M; GAAP EPS $0.17 vs $0.31 YoY; declares $0.08 dividend

## Summary
- Q2 organic revenue declined 2% to $272.6M; reported revenue flat vs prior year.
- GAAP EPS $0.17 vs $0.31 YoY; adjusted EPS $0.40 vs $0.47.
- Cash flow from operations $142.5M, up 18% YoY.
- Board declared $0.08 per share quarterly dividend, payable Feb 26, 2024.
- Dr. Matthew F. McManus appointed President of Diagnostics and Genomics segment.

## SEC filing metadata
- accession: 0001558370-24-000683
- form_type: 8-K
- ticker: TECH
- cik: 0000842023
- company_name: BIO-TECHNE Corp
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/842023/000155837024000683/0001558370-24-000683-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/842023/000155837024000683/tmb-20240201x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000683
- JSON: https://secwatch.observer/filing/0001558370-24-000683.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000683.txt

## Key facts
- Earnings Releases
  BIO-TECHNE Corp reported financial results for second quarter ended December 31, 2023.
  - Period: second quarter ended December 31, 2023
  - Result: reported results
  source text: A copy of the press release issued by Bio-Techne Corporation on February 1, 2024, describing the results of operations for the quarter ended December 31, 2023, and its financial condition as of December 31, 2023 is attached hereto as Exhibit 99.1.
  evidence_url: https://www.sec.gov/Archives/edgar/data/842023/000155837024000683/0001558370-24-000683-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.